Treatment of Schizophrenia With an Omega-3 Fatty Acid (EPA) and Antioxidants

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

99

Participants

Timeline

Start Date

September 30, 2001

Primary Completion Date

April 30, 2004

Study Completion Date

April 30, 2004

Conditions
SchizophreniaSchizophreniform DisordersSchizoaffective DisorderPsychotic Disorders
Interventions
DRUG

Ethyl-eicosapentaenoic acid (EPA)

Capsules, 2 g per day for 16 weeks

DRUG

Vitamins E + C

RRR-alpha-tocopherol 392 mg + slow-release ascorbic acid 1000 mg per day, for 16 weeks

OTHER

Etyl EPA (placebo)

Paraffin oil. Capsules, each 0.5 g.

OTHER

Vitamins E+C (placebo)

Tablets containing dicalciumphosphate

Trial Locations (1)

0320

Aker University Hospital, Oslo

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Diakonhjemmet Hospital

OTHER

collaborator

Stanley Medical Research Institute

OTHER

collaborator

Laxdale Ltd

UNKNOWN

collaborator

Scandinavian Society for Psychopharmacology

UNKNOWN

collaborator

Shipowner Emil Stray's legacy

UNKNOWN

collaborator

Johanne and Einar Eilertsen's research fund

UNKNOWN

collaborator

AstraZeneca

INDUSTRY

collaborator

Solveig and Johan P. Sommer's foundation

UNKNOWN

collaborator

Josef and Haldis Andresen's legacy

UNKNOWN

collaborator

University of Oslo

OTHER

collaborator

Norwegian University of Science and Technology

OTHER

lead

University Hospital, Aker

OTHER